🎉 M&A multiples are live!
Check it out!

Haisco Pharmaceutical Valuation Multiples

Discover revenue and EBITDA valuation multiples for Haisco Pharmaceutical and similar public comparables like Pharming, Galapagos, and Julphar.

Haisco Pharmaceutical Overview

About Haisco Pharmaceutical

Haisco Pharmaceutical Group Co Ltd is a pharmaceutical company based in China. It is mainly engaged in the research, development, manufacture, and sale of drugs for liver disease. Its product portfolio includes parenteral nutrition drugs, antibiotics, anesthetic agents, digestive system drugs and tumour adjuvant drug series. The company's products are being used in first rank hospitals in China.


Founded

2000

HQ

China
Employees

n/a

Website

haisco.com

Financials

LTM Revenue $563M

LTM EBITDA $77.3M

EV

$7.1B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Haisco Pharmaceutical Financials

Haisco Pharmaceutical has a last 12-month revenue of $563M and a last 12-month EBITDA of $77.3M.

In the most recent fiscal year, Haisco Pharmaceutical achieved revenue of $513M and an EBITDA of $103M.

Haisco Pharmaceutical expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Haisco Pharmaceutical valuation multiples based on analyst estimates

Haisco Pharmaceutical P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $513M $532M XXX XXX XXX
Gross Profit $289M $328M XXX XXX XXX
Gross Margin 56% 62% XXX XXX XXX
EBITDA $103M $63.8M XXX XXX XXX
EBITDA Margin 20% 12% XXX XXX XXX
Net Profit $38.2M $40.7M XXX XXX XXX
Net Margin 7% 8% XXX XXX XXX
Net Debt $141M n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Haisco Pharmaceutical Stock Performance

As of April 15, 2025, Haisco Pharmaceutical's stock price is CNY 45 (or $6).

Haisco Pharmaceutical has current market cap of CNY 50.9B (or $7.0B), and EV of CNY 51.6B (or $7.1B).

See Haisco Pharmaceutical trading valuation data

Haisco Pharmaceutical Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$7.1B $7.0B XXX XXX XXX XXX $0.06

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Haisco Pharmaceutical Valuation Multiples

As of April 15, 2025, Haisco Pharmaceutical has market cap of $7.0B and EV of $7.1B.

Haisco Pharmaceutical's trades at 12.6x LTM EV/Revenue multiple, and 91.9x LTM EBITDA.

Analysts estimate Haisco Pharmaceutical's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Haisco Pharmaceutical and 10K+ public comps

Haisco Pharmaceutical Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $7.1B XXX XXX XXX
EV/Revenue 13.4x XXX XXX XXX
EV/EBITDA 111.3x XXX XXX XXX
P/E 120.0x XXX XXX XXX
P/E/Growth 3.1x XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Haisco Pharmaceutical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Haisco Pharmaceutical Valuation Multiples

Haisco Pharmaceutical's NTM/LTM revenue growth is 21%

Haisco Pharmaceutical's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, Haisco Pharmaceutical's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Haisco Pharmaceutical's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Haisco Pharmaceutical and other 10K+ public comps

Haisco Pharmaceutical Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 4% XXX XXX XXX XXX
EBITDA Margin 12% XXX XXX XXX XXX
EBITDA Growth -38% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 33% XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee n/a XXX XXX XXX XXX
S&M Expenses to Revenue 3% XXX XXX XXX XXX
G&A Expenses to Revenue 21% XXX XXX XXX XXX
R&D Expenses to Revenue 17% XXX XXX XXX XXX
Opex to Revenue 59% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Haisco Pharmaceutical Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Haisco Pharmaceutical M&A and Investment Activity

Haisco Pharmaceutical acquired  XXX companies to date.

Last acquisition by Haisco Pharmaceutical was  XXXXXXXX, XXXXX XXXXX XXXXXX . Haisco Pharmaceutical acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Haisco Pharmaceutical

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Haisco Pharmaceutical

When was Haisco Pharmaceutical founded? Haisco Pharmaceutical was founded in 2000.
Where is Haisco Pharmaceutical headquartered? Haisco Pharmaceutical is headquartered in China.
Is Haisco Pharmaceutical publicy listed? Yes, Haisco Pharmaceutical is a public company listed on SHE.
What is the stock symbol of Haisco Pharmaceutical? Haisco Pharmaceutical trades under 002653 ticker.
When did Haisco Pharmaceutical go public? Haisco Pharmaceutical went public in 2012.
Who are competitors of Haisco Pharmaceutical? Similar companies to Haisco Pharmaceutical include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Haisco Pharmaceutical? Haisco Pharmaceutical's current market cap is $7.0B
What is the current revenue of Haisco Pharmaceutical? Haisco Pharmaceutical's last 12-month revenue is $563M.
What is the current EBITDA of Haisco Pharmaceutical? Haisco Pharmaceutical's last 12-month EBITDA is $77.3M.
What is the current EV/Revenue multiple of Haisco Pharmaceutical? Current revenue multiple of Haisco Pharmaceutical is 12.6x.
What is the current EV/EBITDA multiple of Haisco Pharmaceutical? Current EBITDA multiple of Haisco Pharmaceutical is 91.9x.
What is the current revenue growth of Haisco Pharmaceutical? Haisco Pharmaceutical revenue growth between 2023 and 2024 was 4%.
Is Haisco Pharmaceutical profitable? Yes, Haisco Pharmaceutical is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.